uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s Price Target Says the Selloff Went Too Far
uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside. Whether that gap represents opportunity or denial depends on one number that…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
uniQure (NASDAQ:QURE) fell 37.33% in a single session, from a $39.11 close to $24.51, after data showed its Huntington’s disease gene therapy still slowed the disease.
Wall Street’s consensus price target of $68.20 implies 178.25% upside, though targets typically precede major events and may not yet reflect this selloff.
Huntington’s is an inherited brain disorder. No approved treatment slows it. uniQure’s candidate, AMT-130, is a one-time gene therapy, and the company’s value depends almost entirely on its approval.
Investors fled on the direction of travel as the benefit declined between year three and year four of follow-up, and whether $68.20 represents real upside or a number pending revision depends on how you consider that deceleration.
Four-Year Data Showed Less Slowing Than Year Three
uniQure said the high-dose group showed 44% slowing of decline on the cUHDRS, a combined measure of movement, thinking and daily function, at 48 months versus a natural-history control. BioSpace reported the three-year figure was about 75%.
Total functional capacity, which measures daily living, showed a similar trend. BioPharma Dive reported 61% slowing at four years against 67% at three.
The four-year result was not statistically significant, meaning the difference from control was too small to rule out chance. BioSpace also reported that about 53% of the 48-month data was missing, and that the high-dose group had 12 patients.
In a group that small, one patient dropping out or declining faster can sharply shift the percentage. Missing data cuts both ways: sickest patients tend to miss visits, which can flatter results, but gaps also widen error around any benefit claim.
uniQure pushed back, saying the updated natural-history database underestimates disease progression.
A $68.20 Target Built Before the Selloff
The consensus rests on 2 Strong Buy, 9 Buy and 1 Hold ratings.
Institutions hold 97.96% of shares, which means professionals reading the same release did the selling. Stifel’s Paul Matteis called the results “still impressive generally.”
This name trades violently, with a fifty-two-week range of $8.73 to $71.50. It now sits below its two-hundred-day moving average of $29.65. Targets will likely fall, though probably not to the current price.
Approval Is Worth Everything Because Sales Are Near Zero
uniQure sells almost nothing today. Trailing twelve-month revenue was $18.672 million and diluted EPS was -$4.16, so the stock is an option on approval.
The bull case rests on the FDA agreeing that a filing based on the three-year data was reasonable. The four-year update does not replace that package.
Chief executive Matt Kapusta said, “We strongly believe in our data, and what we’ve demonstrated in four years is unprecedented.”
uniQure submitted its application in late summer and requested priority review. The company expects FDA acceptance in the fourth quarter of 2026, with a decision roughly eight months later.
One-time dosing means pricing and reimbursement will drive revenue more than prescription volume, and a first therapy to slow Huntington’s could command unusual pricing. Management expects cash and investments of $810.3 million to fund operations into 2030.
What Would Break the Bull Case
The FDA could reject the filing or demand more evidence. It already wants the confirmatory study well underway and potentially fully enrolled when accelerated approval is granted.
Management expects an advisory committee. The weaker four-year trend will face review there. uniQure also paused higher doses in its Fabry program after Grade 3 liver-enzyme elevations and discontinued its ALS program.
The stock is down 58.74% over one year and up 2.42% year to date, while the S&P 500 is up 12.07% year to date.
Should You Buy or Sell QURE Stock
The setup looks positive for a small position. The regulatory path built on three-year data is intact, and the stock trades below its two-hundred-day average.
Binary biotech is a position-sizing question. Position sizing matters so a rejection is survivable.
For most investors, the SPDR S&P Biotech ETF (NYSEARCA:XBI) is the better choice. It is up 28.73% year to date and holds uniQure at just over 1% of net assets, keeping some approval exposure without single-company risk.
QURE suits investors who can hold through an FDA decision and a likely advisory committee, while XBI suits anyone who wants biotech exposure without one release deciding the outcome.
Contact [email protected] for any questions or corrections.
Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth, cyclical, and dividend equities that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as penny stocks.
